Hidenori Toyoda1, Takashi Kumada. 1. Ogaki Municipal Hospital, Department of Gastroenterology, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan.
Abstract
BACKGROUND: There has been no direct comparison of the antiviral efficacy and the adverse effects of peginterferon (PEG-IFN) alfa-2a and PEG-IFN alfa-2b when used in combination therapy with ribavirin for chronic hepatitis C virus (HCV) infection. OBJECTIVE: A head-to-head comparison of the antiviral efficacy and the adverse effects of PEG-IFN alfa-2a and PEG-IFN alfa-2b was made based on the results from the IDEAL trial, a large, multicenter, prospective, randomized, controlled study performed in the United States to provide guidance for the selection of the right PEG-IFN in clinical settings. METHODS: The results of the IDEAL trial were analyzed. RESULTS/ CONCLUSION: The antiviral efficacy, as well as the adverse effects, of PEG-IFN alfa-2a and PEG-IFN alfa-2b are similar in US patients with HCV genotype 1 when used in a standard dosing regimen in combination with ribavirin.
RCT Entities:
BACKGROUND: There has been no direct comparison of the antiviral efficacy and the adverse effects of peginterferon (PEG-IFN) alfa-2a and PEG-IFN alfa-2b when used in combination therapy with ribavirin for chronic hepatitis C virus (HCV) infection. OBJECTIVE: A head-to-head comparison of the antiviral efficacy and the adverse effects of PEG-IFN alfa-2a and PEG-IFN alfa-2b was made based on the results from the IDEAL trial, a large, multicenter, prospective, randomized, controlled study performed in the United States to provide guidance for the selection of the right PEG-IFN in clinical settings. METHODS: The results of the IDEAL trial were analyzed. RESULTS/ CONCLUSION: The antiviral efficacy, as well as the adverse effects, of PEG-IFN alfa-2a and PEG-IFN alfa-2b are similar in USpatients with HCV genotype 1 when used in a standard dosing regimen in combination with ribavirin.